Axogen, Inc. (AXGN)
| Market Cap | 2.60B +259.1% |
| Revenue (ttm) | 251.17M +23.6% |
| Net Income | -33.55M |
| EPS | -0.68 |
| Shares Out | 53.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 550,025 |
| Open | 46.73 |
| Previous Close | 47.10 |
| Day's Range | 46.29 - 48.39 |
| 52-Week Range | 15.27 - 52.91 |
| Beta | 1.16 |
| Analysts | Strong Buy |
| Price Target | 53.90 (+11.64%) |
| Earnings Date | Jul 29, 2026 |
About AXGN
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $53.9, which is an increase of 11.64% from the latest price.
News
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
AxoGen initiated with a Buy at Truist
Truist initiated coverage of AxoGen (AXGN) with a Buy rating and $60 price target The firm views AxoGen as a “unique high-growth” peripheral nerve repair company, marketing the first and…
AxoGen price target raised to $55 from $50 at Jefferies
Jefferies analyst Michael Sarcone raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps a Buy rating on the shares after a “beat & raise” in…
AxoGen price target raised to $55 from $50 at Canaccord
Canaccord raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps a Buy rating on the shares. The firm said they posted a strong quarter against…
AxoGen price target raised to $53 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $53 from $50 and keeps a Buy rating on the shares. The company reported “robust” sales growth in Q2,…
AxoGen price target raised to $55 from $50 at Citizens
Citizens analyst David Turkaly raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps an Outperform rating on the shares. AxoGen continues to deliver standout growth,…
AxoGen price target raised to $55 from $50 at Jefferies
Jefferies raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps a Buy rating on the shares. Q2 sales were better than consensus, and the company…
Axogen Earnings Call Transcript: Q2 2026
Q2 2026 saw 23.1% revenue growth, led by accelerating Breast market adoption and strong Avance demand. Updated guidance calls for at least 24% revenue growth and 73% gross margin for the year, with robust sales force productivity and continued investment in innovation and evidence generation.
Axogen Slides: Q2 2026
Axogen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Axogen Quarterly report: Q2 2026
Axogen has published its Q2 2026 quarterly earnings report on July 29, 2026.
Axogen Earnings release: Q2 2026
Axogen released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
AxoGen reports Q2 adjusted EPS 12c, consensus 12c
Reports Q2 revenue $69.73M, consensus $67.1M. “We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s (AXGN) strategic plan priorities,” said ...
AxoGen raises FY26 revenue view to $279M from $270M, consensus $270.92M
The company said, “For 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and…
Trace Biosciences announces strategic investment from Axogen
Trace Biosciences announced it has received a strategic investment from Axogen (AXGN) as its technology continues to advance through clinical development. The investment is part of Trace’s Series A fi...
Axogen, Inc. Reports Second Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
Axogen Slides: Corporate presentation
Axogen has posted slides in relation to its latest quarterly earnings report, which was published on July 28, 2026.
Neuronetics appoints Nir Naor as CFO, CLO Andrew Macan to step down
Neuronetics (STIM) announced that Nir Naor will be appointed CFO effective July 23. Most recently, he served as CFO of Axogen (AXGN). Separately, Andrew Macan, executive VP, chief legal officer…
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen Transcript: AGM 2026
The meeting was held virtually, with all director nominees elected, auditor ratified, and executive compensation approved by large majorities. Shareholders had opportunities for questions, and final voting results will be filed in a Form 8-K.
Axogen Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a unified strategic plan focused on peripheral nerve repair, highlighted recent reimbursement wins, and discussed ongoing payer negotiations. Financial guidance remains strong, with operational improvements expected to boost margins, and new clinical data may drive future growth.
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target raised to $48 from $41 at Raymond James
Raymond James raised the firm’s price target on AxoGen (AXGN) to $48 from $41 and keeps an Outperform rating on the shares. Axogen is delivering its strongest growth in five…
AxoGen price target raised to $50 from $45 at Canaccord
Canaccord analyst Caitlin Roberts raised the firm’s price target on AxoGen (AXGN) to $50 from $45 and keeps a Buy rating on the shares. The firm said they posted an…
Axogen Proxy statement: Proxy filing
Axogen filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
AxoGen price target raised to $50 from $39 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $50 from $39 and keeps a Buy rating on the shares following the Q1 sales beat. AxoGen is an…